

State of Oklahoma Oklahoma Health Care Authority Petition for Synagis Authorization

Men	nber Name:		_ Sex:	ID #:	
Date	e of birth:	Current Age:	_(months) Ges	stational age (GA):	(weeks/days)
Pres	scriber Initials (Required)	(confirming GA)	□ Dose re	eceived in hospital. Date	o:
Birth	n Weight:kg	Current Weight:	kg	Date Recorded:	
(e.g	mg/kg IM. Only those doses t j. 1-55 mg = 50 mg vial, 56-11 ry 30 days.	nat require greater than a			
Phy	ysician billing			100 mg/ml: NDC: 60 9	574411301
		Billing Prov	ider Informa	tion	
Provider Phone: Provider Provi				PI	
Spe Spe Prin	ecialist: ecialist Phone: mary Care Provider: P NPI:	Sr	r Information Decialist NPI: Decialist Fax: DP address:		
			iteria		
□ □ t	 Infants and children who are less than 12 months of age, born at 32 weeks' 0 days gestation or earlier and develop Chronic Lung Disease (CLD) of prematurity (require >21% oxygen supplementation for at least 28 days after birth). Infants and children 12 to 24 months of age, born at 32 weeks' 0 days gestation or earlier and develop CLD of prematurity (require >21% oxygen supplementation for at least 28 days after birth) who continue to require medical support (chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen) during the 6 months before the start of the RSV season. Treatment/date received: 				
	Infants up to 12 months of age with moderate-to-severe pulmonary hypertension or with acyanotic heart disease on medications to control congestive heart failure and will require cardiac surgical procedures. Please list medications:				
☐ I	Infants less than 12 months of age, born at 29 weeks' 0 days gestation or earlier. Infants less than 12 months of age, with neuromuscular disease or congenital anomaly that impairs the ability to clear secretions from the upper airway because of ineffective cough. Specify				
	nfants less than 24 months of Specify	age, who undergo cardia	c transplantation	during RSV season.	
	nfants less than 12 months of Specify				
ļ	Infants less than 24 months of age with cystic fibrosis with manifestations of severe lung disease or weight for length less than the 10th percentile. Specify				
	Specify	age, who are profoundly i	mmunocomprom	nised during RSV season.	
Pres	Additional Information:scriber Signature (<i>Require</i>	ed)		Date	
Pleas	se do not send in chart notes. Spe	ecitic information/documental	ion will be request	ed if necessary.	

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit Fax: 1-800-224-4014 Phone: 1-800-522-0114, Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.